カテゴリー： Allied Market Research, 世界, 医療/バイオ

抗血小板剤のグローバル市場（2023-2032）：アデノシン二リン酸（ADP）受容体阻害剤、非可逆的阻害剤シクロオキシゲナーゼ、その他

◆英語タイトル：Antiplatelet Market By Drug Class (Adenosine diphosphate (ADP) receptor inhibitors, Irreversible inhibitors cyclooxygenase, Others), By Route of Administration (Oral, Injectable), By Distribution Channel (Hospital pharmacies, Drug store and retail pharmacies, Online providers): Global Opportunity Analysis and Industry Forecast, 2023-2032

Allied Market Researchが発行した調査報告書（ALD23OCT083）◆商品コード：ALD23OCT083
◆発行会社（リサーチ会社）：Allied Market Research
◆発行日：2023年7月
◆ページ数：259
◆レポート形式：英語 / PDF
◆納品方法：Eメール（受注後24時間以内）
◆調査対象地域：グローバル
◆産業分野：医薬品
◆販売価格オプション（消費税別）
Online Only（1名閲覧、印刷不可）USD3,570 ⇒換算￥542,640見積依頼/購入/質問フォーム
Single User（1名閲覧）USD5,730 ⇒換算￥870,960見積依頼/購入/質問フォーム
Enterprise User（閲覧人数無制限）USD9,600 ⇒換算￥1,459,200見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いに変更可）
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。

❖ レポートの概要 ❖

世界の抗血小板剤市場は、2022年には38億ドルと評価され、2023年から2032年までの年平均成長率は4.2%で、2032年には58億ドルに達すると予測されています。
抗血小板薬としても知られる抗血小板剤は、血栓形成を担う小さな血液細胞である血小板の活性化と凝集を阻害することで、血栓の形成を防ぐ働きをする薬剤の一種です。これらの薬剤は、心臓発作や脳卒中などの心血管系疾患の予防と管理に一般的に使用されています。 
血小板は、傷害後の出血を止める止血プロセスにおいて重要な役割を果たしています。血管が損傷すると、血小板はその部位に付着して凝集し、血栓を形成して傷を塞ぎます。しかし、動脈硬化や不整脈などの特定の病態では、血栓が血管内で不適切に形成され、心臓発作や脳卒中を引き起こす閉塞につながることがあります。抗血小板剤は、血小板の活性化と凝集過程のさまざまな段階を阻害することによって作用します。一般的に使用されている抗血小板剤には、アスピリン、クロピドグレル、チカグレロル、プラスグレルなどがあります。これらの薬剤は、凝固経路に関与する特定の受容体や酵素を阻害することにより、血小板の活性化を抑制します。

抗血小板剤市場は、心臓発作や脳卒中などの心血管疾患の有病率の増加などの要因により、予防・治療手段としての抗血小板剤の需要が高まり、市場の成長を促進しています。例えば、アメリカ協会によると、2020年の脳卒中の有病率は全世界で8,910万人でした。また、虚血性脳卒中は6,820万人、脳内出血は1,890万人、くも膜下出血は810万人です。このように、心血管疾患の増加は抗血小板剤の需要を高め、市場の成長を促進します。 
加えて、抗血小板剤の分野では研究開発が進められており、有効性と安全性が強化された新規薬剤が発見されています。新しく改良された薬剤の導入は市場の成長を刺激し、この分野への投資を誘致します。例えば、Lee's Pharmaceutical Limitedは、Anfibatateの忍容性、安全性、薬物動態を調査するための第1相臨床試験を実施中です。  

さらに、一般に血管形成術として知られる経皮的冠動脈形成術（PCI）は、冠動脈疾患の治療に用いられる外科的処置です。抗血小板剤は、PCI手技において、手技中および手技後の両方で重要な役割を果たしています。したがって、経皮的冠動脈形成術における抗血小板剤の使用量の急増は、抗血小板剤市場の拡大に貢献しています。 

抗血小板剤市場は薬剤クラス、投与経路、流通チャネル、地域に区分されます。薬剤クラス別では、アデノシン二リン酸（ADP）受容体阻害剤、不可逆的阻害剤シクロオキシゲナーゼ、その他に分類されます。
投与経路別では、経口剤と注射剤に分類されます。販売チャネル別では、病院薬局、ドラッグストア・小売薬局、オンラインプロバイダーに分類されます。地域別では、北米（アメリカ、カナダ、メキシコ）、ヨーロッパ（ドイツ、フランス、イギリス、イタリア、スペイン、その他ヨーロッパ）、アジア太平洋（日本、中国、オーストラリア、インド、韓国、その他アジア太平洋）、中南米・中東・アフリカ（ブラジル、南アフリカ、サウジアラビア、その他中南米・中東・アフリカ）にわたって分析しています。 
抗血小板剤市場で事業を展開する主な主要企業には、AstraZeneca plc, Bayer AG, Eli Lilly and Company, Glenmark Pharmaceuticals Limited, Cipla Ltd., Otsuka Pharmaceutical Co., Ltd., Lupin, Sanofi S.A., Daiichi Sankyo Company Limited, and Chiesi Farmaceutici S.p.Aなどが含まれます。

ステークホルダーにとっての主なメリット
本レポートは、2022年から2032年までの抗血小板剤市場分析の市場セグメント、現在の動向、予測、ダイナミクスを定量的に分析し、抗血小板剤市場の有力な機会を特定します。
抗血小板剤の市場機会を特定するため、2022年から2032年までの市場セグメント、現在の動向、予測、動態を定量分析します。
ポーターのファイブフォース分析により、バイヤーとサプライヤーの潜在力を明らかにし、ステークホルダーが利益重視のビジネス決定を下し、サプライヤーとバイヤーのネットワークを強化できるようにします。
抗血小板剤市場のセグメンテーションを詳細に分析することで、市場機会を見極めることができます。
各地域の主要国を世界市場への収益貢献度に応じてマッピングしています。
市場プレイヤーのポジショニングはベンチマーキングを容易にし、市場プレイヤーの現在のポジションを明確に理解することができます。
地域別および世界の抗血小板剤市場動向、主要企業、市場セグメント、応用分野、市場成長戦略の分析を含みます。

本レポートをご購入いただくと、以下の特典があります：
四半期ごとの更新可能です*（コーポレート・ライセンスの場合のみ、表示価格でのご提供となります）
無料のアップデートとして、購入前または購入後に、5社の会社概要を追加可能です。
アナリストによる16時間のサポート可能です。* (購入後、レポートのレビューで追加のデータ要件が見つかった場合、質問や販売後の問い合わせを解決するためにアナリストによる16時間のサポートを受けることができます)
15% の無料カスタマイズ可能です。* （レポートの範囲またはセグメントが要件と一致しない場合、20% は 3 営業日の無料作業に相当し、1 回適用されます。）
5ユーザー・エンタープライズユーザーライセンスの無料データパック可能です。(Excel版レポート）
レポートが6～12ヶ月以上前の場合、無料更新可能です。
24時間優先対応可能です。
産業の最新情報とホワイトペーパーを無料で提供します。

本レポートで可能なカスタマイズ（追加費用とスケジュールが必要です。）
新製品開発／主要企業の製品マトリックス
国、地域、グローバルレベルでの患者/疫学データ
規制ガイドライン
顧客の関心に特化した追加的な企業プロファイル
国または地域の追加分析-市場規模および予測
企業プロファイルの拡張リスト
過去の市場データ
SWOT分析

主要市場セグメント

薬剤クラス別
アデノシン二リン酸（ADP）受容体阻害剤
非可逆的阻害剤 シクロオキシゲナーゼ
その他

投与経路別
経口剤
注射剤

流通経路別
病院薬局
ドラッグストア・小売薬局
オンラインプロバイダー

地域別
北米
アメリカ
カナダ
メキシコ
ヨーロッパ
ドイツ
フランス
イギリス
イタリア
スペイン
その他のヨーロッパ
アジア太平洋
日本
中国
インド
オーストラリア
韓国
その他のアジア太平洋地域
中南米・中東・アフリカ
ブラジル
サウジアラビア
南アフリカ
その他の地域

主な市場プレイヤー
Sanofi S.A.
Glenmark Pharmaceuticals Limited
Cipla Ltd.
Lupin
Bayer AG
Otsuka Pharmaceutical Co., Ltd.
Daiichi Sankyo Company Limited
Chiesi Farmaceutici S.p.A.
AstraZeneca plc
Eli Lilly and Company.

第1章. 序章
第2章. エグゼクティブサマリー
第3章. 市場概要
第4章. 抗血小板剤の市場分析：薬物クラス別
第5章. 抗血小板剤の市場分析：投与経路別
第6章. 抗血小板剤の市場分析：流通チャネル別
第7章. 抗血小板剤の市場分析：地域別
第8章. 競争状況
第9章. 企業情報

❖ レポートの目次 ❖

CHAPTER 1: INTRODUCTION
1.1. Report description
1.2. Key market segments
1.3. Key benefits to the stakeholders
1.4. Research Methodology
1.4.1. Primary research
1.4.2. Secondary research
1.4.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. CXO Perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top impacting factors
3.2.2. Top investment pockets
3.3. Porter’s five forces analysis
3.3.1. High bargaining power of suppliers
3.3.2. Moderate threat of new entrants
3.3.3. Moderate threat of substitutes
3.3.4. Moderate intensity of rivalry
3.3.5. Moderate bargaining power of buyers
3.4. Market dynamics
3.4.1. Drivers
3.4.1.1. Rise in prevalence of cardiovascular diseases
3.4.1.2. Rise in R&D activities
3.4.1.3. Rise in geriatric population

3.4.2. Restraints
3.4.2.1. Side effects of antiplatelets

3.4.3. Opportunities
3.4.3.1. Growth opportunities in emerging markets

3.5. COVID-19 Impact Analysis on the market
CHAPTER 4: ANTIPLATELET MARKET, BY DRUG CLASS
4.1. Overview
4.1.1. Market size and forecast
4.2. Adenosine diphosphate (ADP) receptor inhibitors
4.2.1. Key market trends, growth factors and opportunities
4.2.2. Market size and forecast, by region
4.2.3. Market share analysis by country
4.3. Irreversible inhibitors cyclooxygenase
4.3.1. Key market trends, growth factors and opportunities
4.3.2. Market size and forecast, by region
4.3.3. Market share analysis by country
4.4. Others
4.4.1. Key market trends, growth factors and opportunities
4.4.2. Market size and forecast, by region
4.4.3. Market share analysis by country
CHAPTER 5: ANTIPLATELET MARKET, BY ROUTE OF ADMINISTRATION
5.1. Overview
5.1.1. Market size and forecast
5.2. Oral
5.2.1. Key market trends, growth factors and opportunities
5.2.2. Market size and forecast, by region
5.2.3. Market share analysis by country
5.3. Injectable
5.3.1. Key market trends, growth factors and opportunities
5.3.2. Market size and forecast, by region
5.3.3. Market share analysis by country
CHAPTER 6: ANTIPLATELET MARKET, BY DISTRIBUTION CHANNEL
6.1. Overview
6.1.1. Market size and forecast
6.2. Hospital pharmacies
6.2.1. Key market trends, growth factors and opportunities
6.2.2. Market size and forecast, by region
6.2.3. Market share analysis by country
6.3. Drug store and retail pharmacies
6.3.1. Key market trends, growth factors and opportunities
6.3.2. Market size and forecast, by region
6.3.3. Market share analysis by country
6.4. Online providers
6.4.1. Key market trends, growth factors and opportunities
6.4.2. Market size and forecast, by region
6.4.3. Market share analysis by country
CHAPTER 7: ANTIPLATELET MARKET, BY REGION
7.1. Overview
7.1.1. Market size and forecast By Region
7.2. North America
7.2.1. Key trends and opportunities
7.2.2. Market size and forecast, by Drug Class
7.2.3. Market size and forecast, by Route of Administration
7.2.4. Market size and forecast, by Distribution Channel
7.2.5. Market size and forecast, by country
7.2.5.1. U.S.
7.2.5.1.1. Key market trends, growth factors and opportunities
7.2.5.1.2. Market size and forecast, by Drug Class
7.2.5.1.3. Market size and forecast, by Route of Administration
7.2.5.1.4. Market size and forecast, by Distribution Channel
7.2.5.2. Canada
7.2.5.2.1. Key market trends, growth factors and opportunities
7.2.5.2.2. Market size and forecast, by Drug Class
7.2.5.2.3. Market size and forecast, by Route of Administration
7.2.5.2.4. Market size and forecast, by Distribution Channel
7.2.5.3. Mexico
7.2.5.3.1. Key market trends, growth factors and opportunities
7.2.5.3.2. Market size and forecast, by Drug Class
7.2.5.3.3. Market size and forecast, by Route of Administration
7.2.5.3.4. Market size and forecast, by Distribution Channel
7.3. Europe
7.3.1. Key trends and opportunities
7.3.2. Market size and forecast, by Drug Class
7.3.3. Market size and forecast, by Route of Administration
7.3.4. Market size and forecast, by Distribution Channel
7.3.5. Market size and forecast, by country
7.3.5.1. Germany
7.3.5.1.1. Key market trends, growth factors and opportunities
7.3.5.1.2. Market size and forecast, by Drug Class
7.3.5.1.3. Market size and forecast, by Route of Administration
7.3.5.1.4. Market size and forecast, by Distribution Channel
7.3.5.2. France
7.3.5.2.1. Key market trends, growth factors and opportunities
7.3.5.2.2. Market size and forecast, by Drug Class
7.3.5.2.3. Market size and forecast, by Route of Administration
7.3.5.2.4. Market size and forecast, by Distribution Channel
7.3.5.3. UK
7.3.5.3.1. Key market trends, growth factors and opportunities
7.3.5.3.2. Market size and forecast, by Drug Class
7.3.5.3.3. Market size and forecast, by Route of Administration
7.3.5.3.4. Market size and forecast, by Distribution Channel
7.3.5.4. Italy
7.3.5.4.1. Key market trends, growth factors and opportunities
7.3.5.4.2. Market size and forecast, by Drug Class
7.3.5.4.3. Market size and forecast, by Route of Administration
7.3.5.4.4. Market size and forecast, by Distribution Channel
7.3.5.5. Spain
7.3.5.5.1. Key market trends, growth factors and opportunities
7.3.5.5.2. Market size and forecast, by Drug Class
7.3.5.5.3. Market size and forecast, by Route of Administration
7.3.5.5.4. Market size and forecast, by Distribution Channel
7.3.5.6. Rest of Europe
7.3.5.6.1. Key market trends, growth factors and opportunities
7.3.5.6.2. Market size and forecast, by Drug Class
7.3.5.6.3. Market size and forecast, by Route of Administration
7.3.5.6.4. Market size and forecast, by Distribution Channel
7.4. Asia-Pacific
7.4.1. Key trends and opportunities
7.4.2. Market size and forecast, by Drug Class
7.4.3. Market size and forecast, by Route of Administration
7.4.4. Market size and forecast, by Distribution Channel
7.4.5. Market size and forecast, by country
7.4.5.1. Japan
7.4.5.1.1. Key market trends, growth factors and opportunities
7.4.5.1.2. Market size and forecast, by Drug Class
7.4.5.1.3. Market size and forecast, by Route of Administration
7.4.5.1.4. Market size and forecast, by Distribution Channel
7.4.5.2. China
7.4.5.2.1. Key market trends, growth factors and opportunities
7.4.5.2.2. Market size and forecast, by Drug Class
7.4.5.2.3. Market size and forecast, by Route of Administration
7.4.5.2.4. Market size and forecast, by Distribution Channel
7.4.5.3. India
7.4.5.3.1. Key market trends, growth factors and opportunities
7.4.5.3.2. Market size and forecast, by Drug Class
7.4.5.3.3. Market size and forecast, by Route of Administration
7.4.5.3.4. Market size and forecast, by Distribution Channel
7.4.5.4. Australia
7.4.5.4.1. Key market trends, growth factors and opportunities
7.4.5.4.2. Market size and forecast, by Drug Class
7.4.5.4.3. Market size and forecast, by Route of Administration
7.4.5.4.4. Market size and forecast, by Distribution Channel
7.4.5.5. South Korea
7.4.5.5.1. Key market trends, growth factors and opportunities
7.4.5.5.2. Market size and forecast, by Drug Class
7.4.5.5.3. Market size and forecast, by Route of Administration
7.4.5.5.4. Market size and forecast, by Distribution Channel
7.4.5.6. Rest of Asia-Pacific
7.4.5.6.1. Key market trends, growth factors and opportunities
7.4.5.6.2. Market size and forecast, by Drug Class
7.4.5.6.3. Market size and forecast, by Route of Administration
7.4.5.6.4. Market size and forecast, by Distribution Channel
7.5. LAMEA
7.5.1. Key trends and opportunities
7.5.2. Market size and forecast, by Drug Class
7.5.3. Market size and forecast, by Route of Administration
7.5.4. Market size and forecast, by Distribution Channel
7.5.5. Market size and forecast, by country
7.5.5.1. Brazil
7.5.5.1.1. Key market trends, growth factors and opportunities
7.5.5.1.2. Market size and forecast, by Drug Class
7.5.5.1.3. Market size and forecast, by Route of Administration
7.5.5.1.4. Market size and forecast, by Distribution Channel
7.5.5.2. Saudi Arabia
7.5.5.2.1. Key market trends, growth factors and opportunities
7.5.5.2.2. Market size and forecast, by Drug Class
7.5.5.2.3. Market size and forecast, by Route of Administration
7.5.5.2.4. Market size and forecast, by Distribution Channel
7.5.5.3. South Africa
7.5.5.3.1. Key market trends, growth factors and opportunities
7.5.5.3.2. Market size and forecast, by Drug Class
7.5.5.3.3. Market size and forecast, by Route of Administration
7.5.5.3.4. Market size and forecast, by Distribution Channel
7.5.5.4. Rest of LAMEA
7.5.5.4.1. Key market trends, growth factors and opportunities
7.5.5.4.2. Market size and forecast, by Drug Class
7.5.5.4.3. Market size and forecast, by Route of Administration
7.5.5.4.4. Market size and forecast, by Distribution Channel
CHAPTER 8: COMPETITIVE LANDSCAPE
8.1. Introduction
8.2. Top winning strategies
8.3. Product Mapping of Top 10 Player
8.4. Competitive Dashboard
8.5. Competitive Heatmap
8.6. Top player positioning, 2022
CHAPTER 9: COMPANY PROFILES
9.1. AstraZeneca plc
9.1.1. Company overview
9.1.2. Key Executives
9.1.3. Company snapshot
9.1.4. Operating business segments
9.1.5. Product portfolio
9.1.6. Business performance
9.1.7. Key strategic moves and developments
9.2. Bayer AG
9.2.1. Company overview
9.2.2. Key Executives
9.2.3. Company snapshot
9.2.4. Operating business segments
9.2.5. Product portfolio
9.2.6. Business performance
9.3. Eli Lilly and Company.
9.3.1. Company overview
9.3.2. Key Executives
9.3.3. Company snapshot
9.3.4. Operating business segments
9.3.5. Product portfolio
9.3.6. Business performance
9.4. Otsuka Pharmaceutical Co., Ltd.
9.4.1. Company overview
9.4.2. Key Executives
9.4.3. Company snapshot
9.4.4. Operating business segments
9.4.5. Product portfolio
9.5. Sanofi S.A.
9.5.1. Company overview
9.5.2. Key Executives
9.5.3. Company snapshot
9.5.4. Operating business segments
9.5.5. Product portfolio
9.5.6. Business performance
9.6. Glenmark Pharmaceuticals Limited
9.6.1. Company overview
9.6.2. Key Executives
9.6.3. Company snapshot
9.6.4. Operating business segments
9.6.5. Product portfolio
9.6.6. Business performance
9.7. Cipla Ltd.
9.7.1. Company overview
9.7.2. Key Executives
9.7.3. Company snapshot
9.7.4. Operating business segments
9.7.5. Product portfolio
9.7.6. Business performance
9.8. Lupin
9.8.1. Company overview
9.8.2. Key Executives
9.8.3. Company snapshot
9.8.4. Operating business segments
9.8.5. Product portfolio
9.8.6. Business performance
9.9. Daiichi Sankyo Company Limited
9.9.1. Company overview
9.9.2. Key Executives
9.9.3. Company snapshot
9.9.4. Operating business segments
9.9.5. Product portfolio
9.9.6. Business performance
9.10. Chiesi Farmaceutici S.p.A.
9.10.1. Company overview
9.10.2. Key Executives
9.10.3. Company snapshot
9.10.4. Operating business segments
9.10.5. Product portfolio
9.10.6. Business performance

LIST OF TABLES
TABLE 01. GLOBAL ANTIPLATELET MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
TABLE 02. ANTIPLATELET MARKET FOR ADENOSINE DIPHOSPHATE (ADP) RECEPTOR INHIBITORS, BY REGION, 2022-2032 ($MILLION)
TABLE 03. ANTIPLATELET MARKET FOR IRREVERSIBLE INHIBITORS CYCLOOXYGENASE, BY REGION, 2022-2032 ($MILLION)
TABLE 04. ANTIPLATELET MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
TABLE 05. GLOBAL ANTIPLATELET MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 06. ANTIPLATELET MARKET FOR ORAL, BY REGION, 2022-2032 ($MILLION)
TABLE 07. ANTIPLATELET MARKET FOR INJECTABLE, BY REGION, 2022-2032 ($MILLION)
TABLE 08. GLOBAL ANTIPLATELET MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 09. ANTIPLATELET MARKET FOR HOSPITAL PHARMACIES, BY REGION, 2022-2032 ($MILLION)
TABLE 10. ANTIPLATELET MARKET FOR DRUG STORE AND RETAIL PHARMACIES, BY REGION, 2022-2032 ($MILLION)
TABLE 11. ANTIPLATELET MARKET FOR ONLINE PROVIDERS, BY REGION, 2022-2032 ($MILLION)
TABLE 12. ANTIPLATELET MARKET, BY REGION, 2022-2032 ($MILLION)
TABLE 13. NORTH AMERICA ANTIPLATELET MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
TABLE 14. NORTH AMERICA ANTIPLATELET MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 15. NORTH AMERICA ANTIPLATELET MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 16. NORTH AMERICA ANTIPLATELET MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 17. U.S. ANTIPLATELET MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
TABLE 18. U.S. ANTIPLATELET MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 19. U.S. ANTIPLATELET MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 20. CANADA ANTIPLATELET MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
TABLE 21. CANADA ANTIPLATELET MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 22. CANADA ANTIPLATELET MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 23. MEXICO ANTIPLATELET MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
TABLE 24. MEXICO ANTIPLATELET MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 25. MEXICO ANTIPLATELET MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 26. EUROPE ANTIPLATELET MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
TABLE 27. EUROPE ANTIPLATELET MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 28. EUROPE ANTIPLATELET MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 29. EUROPE ANTIPLATELET MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 30. GERMANY ANTIPLATELET MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
TABLE 31. GERMANY ANTIPLATELET MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 32. GERMANY ANTIPLATELET MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 33. FRANCE ANTIPLATELET MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
TABLE 34. FRANCE ANTIPLATELET MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 35. FRANCE ANTIPLATELET MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 36. UK ANTIPLATELET MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
TABLE 37. UK ANTIPLATELET MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 38. UK ANTIPLATELET MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 39. ITALY ANTIPLATELET MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
TABLE 40. ITALY ANTIPLATELET MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 41. ITALY ANTIPLATELET MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 42. SPAIN ANTIPLATELET MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
TABLE 43. SPAIN ANTIPLATELET MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 44. SPAIN ANTIPLATELET MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 45. REST OF EUROPE ANTIPLATELET MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
TABLE 46. REST OF EUROPE ANTIPLATELET MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 47. REST OF EUROPE ANTIPLATELET MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 48. ASIA-PACIFIC ANTIPLATELET MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
TABLE 49. ASIA-PACIFIC ANTIPLATELET MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 50. ASIA-PACIFIC ANTIPLATELET MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 51. ASIA-PACIFIC ANTIPLATELET MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 52. JAPAN ANTIPLATELET MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
TABLE 53. JAPAN ANTIPLATELET MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 54. JAPAN ANTIPLATELET MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 55. CHINA ANTIPLATELET MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
TABLE 56. CHINA ANTIPLATELET MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 57. CHINA ANTIPLATELET MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 58. INDIA ANTIPLATELET MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
TABLE 59. INDIA ANTIPLATELET MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 60. INDIA ANTIPLATELET MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 61. AUSTRALIA ANTIPLATELET MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
TABLE 62. AUSTRALIA ANTIPLATELET MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 63. AUSTRALIA ANTIPLATELET MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 64. SOUTH KOREA ANTIPLATELET MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
TABLE 65. SOUTH KOREA ANTIPLATELET MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 66. SOUTH KOREA ANTIPLATELET MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 67. REST OF ASIA-PACIFIC ANTIPLATELET MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
TABLE 68. REST OF ASIA-PACIFIC ANTIPLATELET MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 69. REST OF ASIA-PACIFIC ANTIPLATELET MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 70. LAMEA ANTIPLATELET MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
TABLE 71. LAMEA ANTIPLATELET MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 72. LAMEA ANTIPLATELET MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 73. LAMEA ANTIPLATELET MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 74. BRAZIL ANTIPLATELET MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
TABLE 75. BRAZIL ANTIPLATELET MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 76. BRAZIL ANTIPLATELET MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 77. SAUDI ARABIA ANTIPLATELET MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
TABLE 78. SAUDI ARABIA ANTIPLATELET MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 79. SAUDI ARABIA ANTIPLATELET MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 80. SOUTH AFRICA ANTIPLATELET MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
TABLE 81. SOUTH AFRICA ANTIPLATELET MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 82. SOUTH AFRICA ANTIPLATELET MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 83. REST OF LAMEA ANTIPLATELET MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
TABLE 84. REST OF LAMEA ANTIPLATELET MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 85. REST OF LAMEA ANTIPLATELET MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 86. ASTRAZENECA PLC: KEY EXECUTIVES
TABLE 87. ASTRAZENECA PLC: COMPANY SNAPSHOT
TABLE 88. ASTRAZENECA PLC: PRODUCT SEGMENTS
TABLE 89. ASTRAZENECA PLC: PRODUCT PORTFOLIO
TABLE 90. ASTRAZENECA PLC: KEY STRATERGIES
TABLE 91. BAYER AG: KEY EXECUTIVES
TABLE 92. BAYER AG: COMPANY SNAPSHOT
TABLE 93. BAYER AG: PRODUCT SEGMENTS
TABLE 94. BAYER AG: PRODUCT PORTFOLIO
TABLE 95. ELI LILLY AND COMPANY.: KEY EXECUTIVES
TABLE 96. ELI LILLY AND COMPANY.: COMPANY SNAPSHOT
TABLE 97. ELI LILLY AND COMPANY.: PRODUCT SEGMENTS
TABLE 98. ELI LILLY AND COMPANY.: PRODUCT PORTFOLIO
TABLE 99. OTSUKA PHARMACEUTICAL CO., LTD.: KEY EXECUTIVES
TABLE 100. OTSUKA PHARMACEUTICAL CO., LTD.: COMPANY SNAPSHOT
TABLE 101. OTSUKA PHARMACEUTICAL CO., LTD.: PRODUCT SEGMENTS
TABLE 102. OTSUKA PHARMACEUTICAL CO., LTD.: PRODUCT PORTFOLIO
TABLE 103. SANOFI S.A.: KEY EXECUTIVES
TABLE 104. SANOFI S.A.: COMPANY SNAPSHOT
TABLE 105. SANOFI S.A.: PRODUCT SEGMENTS
TABLE 106. SANOFI S.A.: PRODUCT PORTFOLIO
TABLE 107. GLENMARK PHARMACEUTICALS LIMITED: KEY EXECUTIVES
TABLE 108. GLENMARK PHARMACEUTICALS LIMITED: COMPANY SNAPSHOT
TABLE 109. GLENMARK PHARMACEUTICALS LIMITED: PRODUCT SEGMENTS
TABLE 110. GLENMARK PHARMACEUTICALS LIMITED: PRODUCT PORTFOLIO
TABLE 111. CIPLA LTD.: KEY EXECUTIVES
TABLE 112. CIPLA LTD.: COMPANY SNAPSHOT
TABLE 113. CIPLA LTD.: PRODUCT SEGMENTS
TABLE 114. CIPLA LTD.: PRODUCT PORTFOLIO
TABLE 115. LUPIN: KEY EXECUTIVES
TABLE 116. LUPIN: COMPANY SNAPSHOT
TABLE 117. LUPIN: PRODUCT SEGMENTS
TABLE 118. LUPIN: PRODUCT PORTFOLIO
TABLE 119. DAIICHI SANKYO COMPANY LIMITED: KEY EXECUTIVES
TABLE 120. DAIICHI SANKYO COMPANY LIMITED: COMPANY SNAPSHOT
TABLE 121. DAIICHI SANKYO COMPANY LIMITED: PRODUCT SEGMENTS
TABLE 122. DAIICHI SANKYO COMPANY LIMITED: PRODUCT PORTFOLIO
TABLE 123. CHIESI FARMACEUTICI S.P.A.: KEY EXECUTIVES
TABLE 124. CHIESI FARMACEUTICI S.P.A.: COMPANY SNAPSHOT
TABLE 125. CHIESI FARMACEUTICI S.P.A.: PRODUCT SEGMENTS
TABLE 126. CHIESI FARMACEUTICI S.P.A.: PRODUCT PORTFOLIO

❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer
★リサーチレポート[ 抗血小板剤のグローバル市場（2023-2032）：アデノシン二リン酸（ADP）受容体阻害剤、非可逆的阻害剤シクロオキシゲナーゼ、その他(Antiplatelet Market By Drug Class (Adenosine diphosphate (ADP) receptor inhibitors, Irreversible inhibitors cyclooxygenase, Others), By Route of Administration (Oral, Injectable), By Distribution Channel (Hospital pharmacies, Drug store and retail pharmacies, Online providers): Global Opportunity Analysis and Industry Forecast, 2023-2032)]についてメールでお問い合わせはこちらでお願いします。
◆関連リサーチレポート◆
  • インクレチン系薬剤の世界市場2023-2032：機会分析・産業予測
  • マクロライド系抗生物質のグローバル市場（2023-2032）：アジスロマイシン、エリスロマイシン、その他
  • 腸チフス治療薬のグローバル市場（2023-2032）：抗生物質、鎮痛薬、その他
  • 医薬品ドラッグデリバリーの世界市場2023-2032：機会分析・産業予測
  • アテローム性動脈硬化症治療薬の世界市場2023-2032：機会分析・産業予測

    • ◆H&Iグローバルリサーチのお客様（例）◆